action

ACCC Recommits to Cancer Moonshot

On May 11, ACCC Executive Director Christian G. Downs, JD, MHA, was invited to the White House to attend the "Cancer Moonshot: Goals Forum," where the President and First Lady announced a call to action to jumpstart cancer screenings across the nation.

ACCC and AstraZeneca were recognized at the event for their joint effort—the Rural Appalachian Lung Cancer Screening Initiative—to develop and implement person-centered and sustainable approaches to increase lung cancer screening in underserved Appalachian communities. ACCC will bring together an Advisory Committee, composed of ACCC and Oncology State Society stakeholders, American Society of Clinical Oncology (ASCO) leaders, LUNGevity and other patient advocacy representatives, Appalachian Region public health experts, and local lung cancer screening program staff to:

- Identify and address challenges in implementing lung cancer screening programs in rural communities.
- Implement innovative approaches to increase guidelineconcordant lung cancer screening among rural Appalachian communities.



 Assess patient-centered screening education and communication strategies to overcome informational, literacy, and cultural barriers.


Success will be measured by changes in provider attitudes, their self-reported changes in behavior, and patient-reported outcomes. These efforts are part of ACCC's broader Appalachian Community Cancer Alliance, which is made possible by support from Bristol Myers Squibb. Read more at accc-cancer.org/ACCA.

ACCC and ASCO Release Joint Recommendations

On May 19, ASCO and ACCC jointly released recommendations to address the lack of equity, diversity, and inclusion in cancer clinical trials. Published in the *Journal of Clinical Oncology*, "Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement" details specific actions that would engage the entire cancer clinical trial ecosystem in expanding the participation of under-represented individuals in research to advance progress against cancer. Summarized in an infographic, these recommendations focus on key areas, such as:

- 1. Access to clinical trials
- 2. Equity-focused design
- 3. Partnerships among stakeholder groups
- 4. Continuous education and training
- 5. Equity, diversity, and inclusion investment
- 6. Sharing data and strategies.

Access the guidelines online at ascopubs.org/doi/full/10.1200/ JCO.22.00754. Access the infographic online at accc-cancer.org/ asco-accc-2022.



2022 ACCC Virtual Hill Day

As Congress continues to consider legislation to improve access to care after the COVID-19 pandemic, it is more important than ever to share with your congressional representatives the real-world impact that federal health policy has had on patients with cancer and care delivery. ACCC members from 14 states participated in more than 40 virtual meetings with their congressional representatives, sharing the challenges they—and their patients—face and allowing them to help ensure that future legislation reflects the reality of cancer care delivery. Among the 2022 policy asks ACCC members discussed were:

- The **Telehealth Modernization Act** to permanently expand access to Medicare telehealth services by removing geographic and originating site restrictions, which require a patient to live in a rural area and be physically in a doctor's office or clinic to use telehealth services.
- The **Improving Seniors' Timely Access to Care Act of 2021** to standardize and streamline prior authorization processes within the Medicare Advantage program by establishing an electronic prior authorization system that can increase transparency and provide real-time decisions.
- The **DIVERSE Trials Act** to lessen financial burdens for patients participating in clinical trials.
- The Safe Step Act to protect patients from step therapy protocols that delay access to necessary anti-cancer treatments.
- The Medicare Multi-Cancer Early Detection Screening Coverage Act to allow the Centers for Medicare & Medicaid Services to cover these blood-based screening assays.

ACCC Showcases Six Abstracts at ASCO Annual Meeting

The ASCO Annual Meeting, June 3 to 7, 2022, showcased six ACCC abstracts that address some of the current barriers to and disparities in comprehensive cancer care:

- Data for Screening, Offering, and Consenting Patients to Cancer Clinical Trials: Report from an ASCO-ACCC Collaboration
- 2. Generating Meaningful
 Peer-to-Peer Engagement
 Through a Mentor-Led, Small
 Group Social Learning
 Experience on the Evolving
 Standards of Care for
 Advanced HER2+ Breast Cancer
- 3. Building a Multidisciplinary Consortium in Iowa to
- Advance Genetic Counseling and Testing in Patients with Cancer
- 4. Assessing Feasibility and Utility of an Implicit Bias Training Program for Addressing Disparities in Cancer Clinical Trial Participation
- 5. National Organization Addresses Multidisciplinary Oncology Team Burnout and Resiliency Through Multifaceted Presidential Theme Education Initiative
- 6. Using Real-World Data to Assess Variations in Cost and Healthcare Utilization for Patients Diagnosed with Bladder Cancer.

